Cardiotoxicity  	Cardiotoxicity  	 RB	B-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	I-NP
HER2+  	HER2+  	 CD	I-NP
breast  	breast  	 NN	O
cancer  	cancer  	 NN	O
Although  	Although  	 IN	O
having  	having  	 VBG	O
high  	high  	 JJ	O
clinical  	clinical  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
human  	human  	 JJ	O
epidermal  	epidermal  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor-2  	receptor-2  	 NNP	I-NP
( 	( 	 -LRB-	O
HER2+ 	HER2+ 	 NNP	B-NP
)  	)  	 -RRB-	O
metastatic  	metastatic  	 JJ	B-NP
breast  	breast  	 NN	I-NP
cancer 	cancer 	 NN	I-NP
,  	,  	 ,	O
trastuzumab  	trastuzumab  	 NN	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
cardiotoxicity 	cardiotoxicity 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
etiology  	etiology  	 NN	O
and  	and  	 CC	O
pathogenesis  	pathogenesis  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
condition  	condition  	 NN	O
is  	is  	 VBZ	O
currently  	currently  	 RB	O
under  	under  	 IN	O
investigation 	investigation 	 NN	B-NP
.  	.  	 .	O
This  	This  	 DT	O
paper  	paper  	 NN	O
reviews  	reviews  	 VBZ	O
the  	the  	 DT	O
cardiotoxicity 	cardiotoxicity 	 NN	B-NP
,  	,  	 ,	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 JJ	B-NP
use  	use  	 NN	I-NP
and  	and  	 CC	O
discusses  	discusses  	 VBG	O
the  	the  	 DT	O
risk  	risk  	 NN	B-NP
assessment  	assessment  	 NN	I-NP
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
cardiac  	cardiac  	 JJ	B-NP
dysfunction 	dysfunction 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
cardiotoxicity  	cardiotoxicity  	 NN	B-NP
is  	is  	 VBZ	O
lower  	lower  	 JJR	O
when  	when  	 WRB	O
trastuzumab  	trastuzumab  	 NN	B-NP
is  	is  	 VBZ	O
given  	given  	 VBN	O
as  	as  	 IN	O
monotherapy  	monotherapy  	 NNS	B-NP
( 	( 	 -LRB-	O
3 	3 	 CD	O
% 	% 	 NN	O
-7 	-7 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
anthracyclines  	anthracyclines  	 FW	B-NP
+  	+  	 FW	O
trastuzumab  	trastuzumab  	 FW	B-NP
therapy  	therapy  	 FW	I-NP
( 	( 	 -LRB-	O
27 	27 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Type  	Type  	 NNP	O
II  	II  	 NNP	O
cardiac  	cardiac  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
occur  	occur  	 VBP	O
in  	in  	 IN	O
trastuzumab-treated  	trastuzumab-treated  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
do  	do  	 VBP	O
not  	not  	 RB	O
appear  	appear  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
dose-related 	dose-related 	 JJ	O
,  	,  	 ,	O
are  	are  	 VBP	O
not  	not  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
histological  	histological  	 JJ	B-NP
changes 	changes 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
are  	are  	 VBP	O
generally  	generally  	 RB	O
reversible 	reversible 	 JJ	O
.  	.  	 .	O
Several  	Several  	 JJ	O
risk  	risk  	 NN	B-NP
factors  	factors  	 NNS	I-NP
for  	for  	 IN	I-NP
cardiac  	cardiac  	 JJ	I-NP
events  	events  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
identified  	identified  	 VBN	O
and  	and  	 CC	O
assessing  	assessing  	 VBG	B-NP
levels  	levels  	 NNS	I-NP
of  	of  	 IN	O
troponin  	troponin  	 VBG	O
I  	I  	 PRP	O
and  	and  	 CC	O
N-terminal  	N-terminal  	 JJ	B-NP
pro-brain  	pro-brain  	 JJ	I-NP
B-type  	B-type  	 JJ	I-NP
natriuretic  	natriuretic  	 JJ	I-NP
peptide  	peptide  	 NN	I-NP
before  	before  	 IN	O
and  	and  	 CC	O
after  	after  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 NNS	B-NP
may  	may  	 MD	O
allow  	allow  	 VB	O
early  	early  	 JJ	O
detection  	detection  	 NN	O
of  	of  	 IN	O
cardiotoxicity 	cardiotoxicity 	 NN	B-NP
.  	.  	 .	O
A  	A  	 DT	O
symptomatic  	symptomatic  	 NN	O
and  	and  	 CC	O
functional  	functional  	 JJ	B-NP
evaluation  	evaluation  	 NN	I-NP
scheme  	scheme  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
indicated  	indicated  	 VBD	O
for  	for  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 NN	B-NP
has  	has  	 VBZ	O
also  	also  	 RB	O
been  	been  	 VBN	O
proposed  	proposed  	 VBN	O
to  	to  	 TO	O
work  	work  	 VB	O
alongside  	alongside  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
heart  	heart  	 NN	B-NP
failure 	failure 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
cardiac  	cardiac  	 JJ	B-NP
dysfunction  	dysfunction  	 NNS	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 NNS	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
justified  	justified  	 VBN	O
given  	given  	 VBN	O
the  	the  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
risk  	risk  	 NN	O
is  	is  	 VBZ	O
lower  	lower  	 JJR	O
when  	when  	 WRB	O
trastuzumab  	trastuzumab  	 NN	B-NP
is  	is  	 VBZ	O
given  	given  	 VBN	O
as  	as  	 IN	O
monotherapy 	monotherapy 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
paradigm  	paradigm  	 NN	O
for  	for  	 IN	O
cardiologists  	cardiologists  	 NN	O
remains  	remains  	 VBZ	O
the  	the  	 DT	O
same 	same 	 JJ	O
:  	:  	 :	O
treat  	treat  	 VB	O
the  	the  	 DT	O
cancer  	cancer  	 NN	O
effectively  	effectively  	 RB	O
whilst  	whilst  	 VBP	O
preventing  	preventing  	 VBG	B-NP
cardiotoxicity 	cardiotoxicity 	 NNS	I-NP
.  	.  	 .	O
